Citi lifts ResMed's ASX-listed stock's target price after FX, valuation updates

By Reuters News

** Citi expects ResMed RMD.N, to report Q1 sales growth of 3.3%, including a 3% headwind from the absence of Astral ventilator sales and the impact of the MatrixCare divestment

** Brokerage said it is broadly in line with consensus on revenue but about 2% below consensus on EPS due to a slightly lower gross margin forecast and a higher tax rate

** Says investor caution continues to be influenced by uncertainty around competitor Philips' PHG.AS return to the US market, although it said it has no evidence that such a return is imminent

** "We continue to see weight loss drugs as a difficult-to-quantify tailwind" — Citi

** Brokerage updates foreign-exchange assumptions, its valuation date and peer multiples

** Citi hikes ResMed's Australian-listed shares to A$34, while its US-listed share target remains unchanged at $240

** ASX-listed stock down over 6% YTD, as of last close

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.